P=N/A, N=15, Completed, Queen Mary University of London | Active, not recruiting --> Completed

One proposed mechanism for the development of both hematologic malignancies in this patient is the acquisition of a KMT2A rearrangement, raising the possibility of clonal evolution resulting in therapy-related or secondary leukemia. Another explanation is the presence of a common clonal stem cell progenitor harboring a JAK3 mutation.

P2, N=20, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Apr 2026 | Trial primary completion date: Mar 2027 --> Apr 2025

P1, N=8, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | Trial completion date: Dec 2029 --> Sep 2025

P2, N=48, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jan 2026 --> Jan 2027

P2, N=20, Not yet recruiting, Case Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=57, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=30 --> 57

Continued studies evaluating JAK inhibitors in patients with T-PLL are warranted. This trial was registered at www.clinicaltrials.gov as #NCT03989466.

P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2025 --> Jul 2026

P1/2, N=29, Recruiting, Washington University School of Medicine | Trial completion date: Apr 2031 --> Apr 2033 | Trial primary completion date: Apr 2026 --> Apr 2028

P1, N=2, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 2

P3, N=16, Terminated, Genzyme, a Sanofi Company | Active, not recruiting --> Terminated; Enrolment formally closed earlier than planned due to recruitment challenges.